New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 26, 2012
10:23 EDTBSX, MDT, STJBoston Scientific rises after Citi sees Durata coming off market
Boston Scientific (BSX) is climbing after Citigroup analyst Matthew Dodds upgraded the stock to Buy from Neutral in a note to investors earlier today. Durata cables made by St. Jude (STJ), a Boston Scientific competitor, will likely be taken off the market within six months, Dodds believes. Earlier this year a study found that Durata cables can fray when they rub against another object. Boston Scientific will benefit significantly from the withdrawal of St. Jude's cables, which are used to connect defibrillators to the heart, Dodds wrote. If Durata cables are removed from the market, Boston Scientific would obtain 41% of the $338M in revenue that St. Jude would lose, the analyst predicted. Medtronic (MDT) will garner 29% of St. Jude's lost sales, adds Dodds. The analyst increased his price target on Boston Scientific to $7.30 from $5.30. In mid-morning trading, Boston Scientific climbed 19c, or 3.40%, to $5.78, while St. Jude fell 35c, or 1.09%, to $31.68.
News For BSX;STJ;MDT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
<< 1 | 2 | all recent news | >>
May 15, 2015
14:01 EDTSTJSt. Jude Medical reports positive results from Allure Quadra CRT-P System
St. Jude Medical announced the presentation of important data supporting the first and only quadripolar cardiac resynchronization therapy pacemaker system in the U.S., during the Heart Rhythm Society's 36th annual scientific sessions. The Allure Quadra CRT-P system, with the Quartet Quadripolar LV Lead is associated with a 63% reduction in the need to replace the lead or deactivate CRT following implant. Quadripolar LV pacing using SJM quadripolar CRT-Ds or CRT-Ps and an SJM quadripolar lead provides physicians with multiple pacing options to avoid phrenic nerve stimulation and allow for optimal treatment delivery without the need to replace or deactivate the therapy. An analysis evaluating more than 3,000 patients implanted with a CRT-P (1,325 with a quadripolar lead vs. 1,930 with a bipolar lead) looked at whether the known decreased need to replace or deactivate LV leads associated with SJM quadripolar CRT-Ds and the Quartet LV lead also extends to St. Jude Medical quadripolar CRT-Ps. The retrospective data analysis was presented in a session titled Quadripolar Leads are Associated with Fewer LV Lead Replacements and Deactivations in CRT-P Patients by Dr. Mintu P. Turakhia, who led the investigation. The data show that patients with the Quartet LV lead were 63% less likely to undergo lead replacement or deactivation of CRT compared to the patients with bipolar leads.
13:33 EDTMDTMedtronic: TYRX antibacterial envelope reduces cardiac device infection rates
Subscribe for More Information
10:29 EDTBSXAmerican Urological Association to hold an annual meeting
Subscribe for More Information
09:31 EDTBSXAmerican Thoracic Society to hold a conference
ATS 2015 Conference is being held in Denver on May 15-20.
08:45 EDTSTJSt. Jude Medical management to meet with Leerink
Subscribe for More Information
08:41 EDTSTJSt. Jude Medical management to meet with Leerink
Subscribe for More Information
08:12 EDTMDTMedtronic Micra TPS meets initial safety, performance measures
Subscribe for More Information
<< 1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use